Non-invasive delivery strategies for biologics

[1]  Samir Mitragotri,et al.  Ionic liquids for oral insulin delivery , 2018, Proceedings of the National Academy of Sciences.

[2]  S. Balu-Iyer,et al.  Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins. , 2018, Journal of pharmaceutical sciences.

[3]  Pamela A. Silver,et al.  Engineering bacteria for diagnostic and therapeutic applications , 2018, Nature Reviews Microbiology.

[4]  B. Sugarman,et al.  Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects , 2018, BioDrugs.

[5]  S. Mitragotri,et al.  Ionic liquids for addressing unmet needs in healthcare , 2018, Bioengineering & translational medicine.

[6]  Zhen Gu,et al.  A melanin-mediated cancer immunotherapy patch , 2017, Science Immunology.

[7]  S. Lai,et al.  A blueprint for robust crosslinking of mobile species in biogels with weakly adhesive molecular anchors , 2017, Nature Communications.

[8]  David J Brayden,et al.  Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles , 2017, Current opinion in pharmacology.

[9]  R. Wasserman.  Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. , 2017, Immunotherapy.

[10]  T. K. Maiti,et al.  Unveiling the Interaction between Fatty-Acid-Modified Membrane and Hydrophilic Imidazolium-Based Ionic Liquid: Understanding the Mechanism of Ionic Liquid Cytotoxicity. , 2017, The journal of physical chemistry. B.

[11]  Jaykaran Charan,et al.  Monoclonal Antibodies: A Review. , 2017, Current clinical pharmacology.

[12]  S. Mitragotri,et al.  Transdermal Protein Delivery Using Choline and Geranate (CAGE) Deep Eutectic Solvent , 2017, Advanced healthcare materials.

[13]  L. McKinnon,et al.  Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women , 2017, Science.

[14]  M. Nostro,et al.  Cell Therapy for Type 1 Diabetes: Current and Future Strategies , 2017, Current Diabetes Reports.

[15]  Shikha Baghel Chauhan.  Penetration Enhancement Techniques , 2017 .

[16]  M. Prausnitz,et al.  Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes , 2017, The AAPS Journal.

[17]  Yanan Cui,et al.  Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system , 2017, Drug development and industrial pharmacy.

[18]  L. Shea,et al.  Advances in islet encapsulation technologies , 2016, Nature Reviews Drug Discovery.

[19]  E. Mastrobattista,et al.  Drug delivery with living cells. , 2016, Advanced drug delivery reviews.

[20]  David J Brayden,et al.  Oral delivery of peptides: opportunities and issues for translation. , 2016, Advanced drug delivery reviews.

[21]  David J Brayden,et al.  Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. , 2016, Advanced drug delivery reviews.

[22]  E. Wolf,et al.  Progress in Clinical Encapsulated Islet Xenotransplantation. , 2016, Transplantation.

[23]  Samir Mitragotri,et al.  Intestinal mucoadhesive devices for oral delivery of insulin , 2016, Bioengineering & translational medicine.

[24]  Mahmoud Kamal Ahmadi,et al.  In situ pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector , 2016, Science Advances.

[25]  Zhen Gu,et al.  Microneedles Integrated with Pancreatic Cells and Synthetic Glucose‐Signal Amplifiers for Smart Insulin Delivery , 2016, Advanced materials.

[26]  V. Préat,et al.  Reformulating cyclosporine A (CsA): More than just a life cycle management strategy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[27]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[28]  Samir Mitragotri,et al.  De Novo Design of Skin‐Penetrating Peptides for Enhanced Transdermal Delivery of Peptide Drugs , 2016, Advanced healthcare materials.

[29]  S. Mitragotri,et al.  Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices , 2016, Annals of Biomedical Engineering.

[30]  Norma E. Conner,et al.  Advances and Challenges , 2016, The American journal of hospice & palliative care.

[31]  Robert Langer,et al.  Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates , 2016, Nature Biotechnology.

[32]  Matthew A. Bochenek,et al.  Long term Glycemic Control Using Polymer Encapsulated, Human Stem-Cell Derived β-cells in Immune Competent mice , 2016, Nature Medicine.

[33]  Jaimini Cegla,et al.  Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery , 2015, Annals of clinical biochemistry.

[34]  M. Al-Tabakha.  Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Meng Chen,et al.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection , 2015, Patient preference and adherence.

[36]  Zhen Gu,et al.  Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery , 2015, Proceedings of the National Academy of Sciences.

[37]  Amit Jain,et al.  Cyclosporine A loaded self-nanoemulsifying drug delivery system (SNEDDS): implication of a functional excipient based co-encapsulation strategy on oral bioavailability and nephrotoxicity , 2015 .

[38]  Yong Wang,et al.  Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates , 2015, Nature materials.

[39]  Shirui Mao,et al.  Recent advances in controlled pulmonary drug delivery. , 2015, Drug discovery today.

[40]  Robert Langer,et al.  Microneedles for drug delivery via the gastrointestinal tract. , 2015, Journal of pharmaceutical sciences.

[41]  Yahya E Choonara,et al.  A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. , 2014, Biotechnology advances.

[42]  Driton Vllasaliu,et al.  Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. , 2014, Molecular pharmaceutics.

[43]  Samir Mitragotri,et al.  An overview of clinical and commercial impact of drug delivery systems. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[44]  J. Kling.  Sanofi to propel inhalable insulin Afrezza into market , 2014, Nature Biotechnology.

[45]  S. Edelman,et al.  Inhaled insulin: a breath of fresh air? A review of inhaled insulin. , 2014, Clinical therapeutics.

[46]  J. Braeckman,et al.  Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study , 2014, Archives of medical science : AMS.

[47]  S. Mitragotri,et al.  Topical delivery of siRNA into skin using SPACE-peptide carriers. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[48]  R. Langer,et al.  Skin permeabilization for transdermal drug delivery: recent advances and future prospects , 2014, Expert opinion on drug delivery.

[49]  R. Langer,et al.  Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery , 2013, Science Translational Medicine.

[50]  Patrick Couvreur,et al.  Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.

[51]  A. Fathallah,et al.  Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective , 2013, The AAPS Journal.

[52]  C. Lehr,et al.  Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. , 2013, The Lancet. Respiratory medicine.

[53]  Kinam Park,et al.  Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. , 2013, Advanced drug delivery reviews.

[54]  Majella E Lane,et al.  Skin penetration enhancers. , 2013, International journal of pharmaceutics.

[55]  A. Hickey.  Back to the future: inhaled drug products. , 2013, Journal of pharmaceutical sciences.

[56]  P. Carter,et al.  Antibody-drug conjugates in cancer therapy. , 2013, Annual review of medicine.

[57]  Tejal A Desai,et al.  Multi-reservoir bioadhesive microdevices for independent rate-controlled delivery of multiple drugs. , 2012, Small.

[58]  T. Desai,et al.  Emerging microtechnologies for the development of oral drug delivery devices. , 2012, Advanced drug delivery reviews.

[59]  E. Azizi,et al.  Cell‐penetrating Peptides as a Novel Transdermal Drug Delivery System , 2012, Chemical biology & drug design.

[60]  Jung-Hwan Park,et al.  Microneedles for drug and vaccine delivery. , 2012, Advanced drug delivery reviews.

[61]  H. Mach,et al.  High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. , 2012, Therapeutic delivery.

[62]  Laura M Ensign,et al.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.

[63]  Y. Vugmeyster,et al.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. , 2012, World journal of biological chemistry.

[64]  D. Mager,et al.  Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats , 2012, Pharmaceutical Research.

[65]  S. Gough,et al.  Bydureon: long‐acting exenatide for once‐weekly injection , 2012 .

[66]  S. Mitragotri,et al.  Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer , 2011, Proceedings of the National Academy of Sciences.

[67]  K. Vávrová,et al.  Ammonium carbamates as highly active transdermal permeation enhancers with a dual mechanism of action. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[68]  R. Patlolla,et al.  Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery , 2010, Molecular membrane biology.

[69]  Zulkar N. K. Mohammed,et al.  Mucoadhesive drug delivery system: An overview , 2010, Journal of advanced pharmaceutical technology & research.

[70]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[71]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[72]  Stephen C Alley,et al.  Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.

[73]  M. Moniruzzaman,et al.  Ionic liquid-assisted transdermal delivery of sparingly soluble drugs. , 2010, Chemical communications.

[74]  S. Mitragotri,et al.  Enhancement of transdermal drug delivery via synergistic action of chemicals. , 2009, Biochimica et biophysica acta.

[75]  Shana O Kelley,et al.  Recent advances in the use of cell-penetrating peptides for medical and biological applications. , 2009, Advanced drug delivery reviews.

[76]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[77]  R. Cone,et al.  Barrier properties of mucus. , 2009, Advanced drug delivery reviews.

[78]  Gabriel Wittum,et al.  The Role of Corneocytes in Skin Transport Revised—A Combined Computational and Experimental Approach , 2009, Pharmaceutical Research.

[79]  T. Schöndorf,et al.  Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. , 2009, Diabetes technology & therapeutics.

[80]  Allan S. Hoffman,et al.  The origins and evolution of "controlled" drug delivery systems. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[81]  Samir Mitragotri,et al.  Micro-scale devices for transdermal drug delivery. , 2008, International journal of pharmaceutics.

[82]  J. S. Suk,et al.  Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. , 2008, Angewandte Chemie.

[83]  J. Brandner,et al.  The skin: an indispensable barrier , 2008, Experimental dermatology.

[84]  Robert Langer,et al.  Transdermal drug delivery , 2008, Nature Biotechnology.

[85]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[86]  Mark R. Prausnitz,et al.  Effect of Microneedle Design on Pain in Human Volunteers , 2008, The Clinical journal of pain.

[87]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[88]  S. Mitragotri,et al.  Safe and Effective Permeation Enhancers for Oral Drug Delivery , 2008, Pharmaceutical Research.

[89]  Wei Yang,et al.  Inhaled nanoparticles--a current review. , 2008, International journal of pharmaceutics.

[90]  L. Heinemann.  The Failure of Exubera: Are We Beating a Dead Horse? , 2008, Journal of diabetes science and technology.

[91]  J. Selam.  Inhaled Insulin: Promises and Concerns , 2008, Journal of diabetes science and technology.

[92]  L. Schulmeister.  Managing vesicant extravasations. , 2008, The oncologist.

[93]  S. Mitragotri,et al.  Mechanistic Analysis of Chemical Permeation Enhancers for Oral Drug Delivery , 2008, Pharmaceutical Research.

[94]  Mark R Prausnitz,et al.  Transdermal delivery enhanced by magainin pore-forming peptide. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[95]  Simon W. Jones,et al.  Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. , 2007, Bioconjugate chemistry.

[96]  Patrick S. Stayton,et al.  Conjugates of stimuli-responsive polymers and proteins , 2007 .

[97]  G. Frost.  Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration , 2007, Expert opinion on drug delivery.

[98]  K. Girish,et al.  The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. , 2007, Life sciences.

[99]  J. Rosenstock,et al.  Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes , 2007, Diabetes Care.

[100]  Justin Hanes,et al.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.

[101]  Maria Ponec,et al.  The skin barrier in healthy and diseased state. , 2006, Biochimica et biophysica acta.

[102]  Simon Cawthorne,et al.  Particle engineering techniques for inhaled biopharmaceuticals. , 2006, Advanced drug delivery reviews.

[103]  P. Winner,et al.  Nasal Delivery of Antimigraine Drugs: Clinical Rationale and Evidence Base , 2006, Headache.

[104]  A. Hickey.  Inhalation aerosols : physical and biological basis for therapy , 2006 .

[105]  N. Peppas,et al.  Is the oral route possible for peptide and protein drug delivery? , 2006, Drug discovery today.

[106]  Samir Mitragotri,et al.  Current status and future prospects of needle-free liquid jet injectors , 2006, Nature Reviews Drug Discovery.

[107]  Erik Remaut,et al.  A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[108]  Mark G. Allen,et al.  Polymer Microneedles for Controlled-Release Drug Delivery , 2006, Pharmaceutical Research.

[109]  Wenjuan Yang,et al.  Transdermal protein delivery by a coadministered peptide identified via phage display , 2006, Nature Biotechnology.

[110]  B. Silverman,et al.  Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. , 2006, Alcoholism, clinical and experimental research.

[111]  Gregory W. Sluggett,et al.  EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. , 2005, Diabetes technology & therapeutics.

[112]  A. Bernkop‐Schnürch,et al.  Comparison of the mucoadhesive properties of various polymers. , 2005, Advanced drug delivery reviews.

[113]  D. Geller.  Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. , 2005, Respiratory care.

[114]  P. Anderson.  History of aerosol therapy: liquid nebulization to MDIs to DPIs. , 2005, Respiratory care.

[115]  A. Hickey,et al.  Dry powder inhaler formulation. , 2005, Respiratory care.

[116]  K. Jain.  Targeted Drug Delivery for Cancer , 2005 .

[117]  Tejal A Desai,et al.  Gastrointestinal patch systems for oral drug delivery. , 2005, Drug discovery today.

[118]  J. Nicolazzo,et al.  Buccal penetration enhancers--how do they really work? , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[119]  Lokesh Joshi,et al.  Comparative Study of the Skin Penetration of Protein Transduction Domains and a Conjugated Peptide , 2005, Pharmaceutical Research.

[120]  D. Sawamura,et al.  Leuprorelin acetate granulomas: case reports and review of the literature , 2005, The British journal of dermatology.

[121]  Jan Holmgren,et al.  Mucosal immunity and vaccines , 2005, Nature Medicine.

[122]  Samir Mitragotri,et al.  Healing sound: the use of ultrasound in drug delivery and other therapeutic applications , 2005, Nature Reviews Drug Discovery.

[123]  S. Nyberg,et al.  Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[124]  S. Rossi,et al.  Buccal drug delivery: A challenge already won? , 2005, Drug discovery today. Technologies.

[125]  R. G. Thorne,et al.  Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration , 2004, Neuroscience.

[126]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[127]  Lawrence Blonde,et al.  Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.

[128]  Samir Mitragotri,et al.  Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[129]  B. Toole,et al.  Hyaluronan: from extracellular glue to pericellular cue , 2004, Nature Reviews Cancer.

[130]  Joseph C Cappelleri,et al.  Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. , 2004, Diabetes care.

[131]  S. Benita,et al.  Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[132]  Mark R Prausnitz,et al.  Microneedles for transdermal drug delivery. , 2004, Advanced drug delivery reviews.

[133]  Hongyan He,et al.  Design of a novel hydrogel-based intelligent system for controlled drug release. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[134]  S. Mitragotri,et al.  Current status and future potential of transdermal drug delivery , 2004, Nature Reviews Drug Discovery.

[135]  Fakhrul Ahsan,et al.  Absorption enhancers in pulmonary protein delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[136]  M. Dolovich,et al.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.

[137]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[138]  Anthony J. Hickey,et al.  Pharmaceutical Inhalation Aerosol Technology , 2003 .

[139]  Richard Dalby,et al.  Inhalation therapy: technological milestones in asthma treatment. , 2003, Advanced drug delivery reviews.

[140]  O. Pillai,et al.  Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[141]  I. Gómez-Orellana,et al.  Challenges for the oral delivery of macromolecules , 2003, Nature Reviews Drug Discovery.

[142]  L. Illum.  Nasal drug delivery--possibilities, problems and solutions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[143]  Stephen F Badylak,et al.  The extracellular matrix as a scaffold for tissue reconstruction. , 2002, Seminars in cell & developmental biology.

[144]  S. Garg,et al.  Permeability issues in nasal drug delivery. , 2002, Drug discovery today.

[145]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[146]  P. Gupta,et al.  Hydrogels: from controlled release to pH-responsive drug delivery. , 2002, Drug discovery today.

[147]  H. Junginger,et al.  Oral drug absorption enhancement by chitosan and its derivatives. , 2001, Advanced drug delivery reviews.

[148]  K Takada,et al.  Retention and transit of intestinal mucoadhesive films in rat small intestine. , 2001, International journal of pharmaceutics.

[149]  Atilla Abidin or A. Hincal,et al.  Drug permeation enhancement via buccal route: possibilities and limitations. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[150]  V. Préat,et al.  Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[151]  M I Ugwoke,et al.  The biopharmaceutical aspects of nasal mucoadhesive drug delivery , 2001, The Journal of pharmacy and pharmacology.

[152]  Y. Kalia,et al.  Transdermal drug delivery: overcoming the skin's barrier function. , 2000, Pharmaceutical science & technology today.

[153]  E. Ryan,et al.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.

[154]  B. Aungst,et al.  Intestinal permeation enhancers. , 2000, Journal of pharmaceutical sciences.

[155]  J Kristl,et al.  Optimisation of floating matrix tablets and evaluation of their gastric residence time. , 2000, International journal of pharmaceutics.

[156]  V. Sinha,et al.  Permeation Enhancers for Transdermal Drug Delivery , 2000, Drug development and industrial pharmacy.

[157]  R. Langer,et al.  Formulation and Physical Characterization of Large Porous Particles for Inhalation , 1999, Pharmaceutical Research.

[158]  N. Peppas,et al.  Oral delivery of insulin using pH-responsive complexation gels. , 1999, Journal of pharmaceutical sciences.

[159]  Carino,et al.  Oral insulin delivery. , 1999, Advanced drug delivery reviews.

[160]  M. Prausnitz,et al.  A practical assessment of transdermal drug delivery by skin electroporation. , 1999, Advanced drug delivery reviews.

[161]  K. Matsuzaki,et al.  Magainins as paradigm for the mode of action of pore forming polypeptides. , 1998, Biochimica et biophysica acta.

[162]  R. Langer,et al.  Recent advances in pulmonary drug delivery using large, porous inhaled particles. , 1998, Journal of applied physiology.

[163]  M. Allen,et al.  Microfabricated microneedles: a novel approach to transdermal drug delivery. , 1998, Journal of pharmaceutical sciences.

[164]  P. Swaan.  Recent Advances in Intestinal Macromolecular Drug Delivery via Receptor-Mediated Transport Pathways , 1998, Pharmaceutical Research.

[165]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[166]  A. Fasano,et al.  Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. , 1997, The Journal of clinical investigation.

[167]  W. Ritschel.  Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. , 1996, Clinical transplantation.

[168]  R. Borchardt,et al.  Structural requirements for intestinal absorption of peptide drugs , 1996 .

[169]  Akira Tsuji,et al.  Carrier-Mediated Intestinal Transport of Drugs , 1996, Pharmaceutical Research.

[170]  R. Niven,et al.  The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation , 1996 .

[171]  T. Fujita,et al.  Improvement of intestinal absorption of human calcitonin by chemical modification with fatty acids : synergistic effects of acylation and absorption enhancers , 1996 .

[172]  Gerrit Borchard,et al.  The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro , 1996 .

[173]  J. Grant.  Promise and progress , 1995 .

[174]  P. Constantinides,et al.  Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects , 1995, Pharmaceutical Research.

[175]  R. Thorne,et al.  Quantitative analysis of the olfactory pathway for drug delivery to the brain , 1995, Brain Research.

[176]  S. Mitragotri,et al.  Ultrasound-mediated transdermal protein delivery , 1995, Science.

[177]  M. Zach.  The founding and growth of Pediatric pulmonology: A European perspective , 1995, Pediatric pulmonology.

[178]  Akira Yamamoto,et al.  Effects of Various Protease Inhibitors on the Intestinal Absorption and Degradation of Insulin in Rats , 1994, Pharmaceutical Research.

[179]  P. Lacy,et al.  Protection of Encapsulated Human Islets Implanted Without Immunosuppression in Patients With Type I or Type II Diabetes and in Nondiabetic Control Subjects , 1994, Diabetes.

[180]  X. Zhou.  Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs , 1994 .

[181]  Paolo Colombo,et al.  Swelling-controlled release in hydrogel matrices for oral route , 1993 .

[182]  L. Bachrach,et al.  Two-year results of treatment with depot leuprolide acetate for central precocious puberty. , 1992, The Journal of pediatrics.

[183]  D. Wall,et al.  (D) Routes of delivery: Case studies , 1992 .

[184]  L. Illum,et al.  (D) Routes of delivery: Case studies , 1992 .

[185]  F T Gentile,et al.  Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. , 1991, Science.

[186]  J. Kolars,et al.  First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.

[187]  Hugh N. Nellans,et al.  B) Mechanisms of peptide and protein absorption , 1991 .

[188]  R. Conradi,et al.  B) Mechanisms of peptide and protein absorption , 1991 .

[189]  J. D. Miller,et al.  Lupron**TAP Pharmaceuticals, North Chicago, Illinois. depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study ††Supported by a grant from TAP Pharmaceuticals, North Chicago, Illinois. , 1990 .

[190]  A. Sun,et al.  Reversal of Diabetes in BB Rats by Transplantation of Encapsulated Pancreatic Islets , 1990, Diabetes.

[191]  R. Clemons,et al.  Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty. , 1989, The Journal of clinical endocrinology and metabolism.

[192]  D Rodbard,et al.  Computer Simulation of Plasma Insulin and Glucose Dynamics After Subcutaneous Insulin Injection , 1989, Diabetes Care.

[193]  Akira Yamamoto,et al.  Penetration and enzymatic barriers to peptide and protein absorption , 1989 .

[194]  Christian Binder,et al.  Modeling absorption kinetics of subcutaneous injected soluble insulin , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[195]  M. Hussain,et al.  Improved Buccal Delivery of Opioid Analgesics and Antagonists with Bitterless Prodrugs , 1988, Pharmaceutical Research.

[196]  J. J. Batenburg,et al.  The pulmonary surfactant system: biochemical aspects and functional significance. , 1988, Physiological reviews.

[197]  W. Shi,et al.  Transdermal Iontophoretic Delivery of Therapeutic Peptides/Proteins I: Insulin , 1987, Annals of the New York Academy of Sciences.

[198]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[199]  P. Bergstresser,et al.  Epidermal ‘turnover time’—a new examination , 1977, The British journal of dermatology.

[200]  D. Matthews.  Intestinal absorption of peptides. , 1975, Physiological reviews.

[201]  G. Smirnov,et al.  Possibilities and Limitations , 1970 .

[202]  L. S. Kind,et al.  Allergic Reactions to Hyaluronidase.∗ , 1961, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[203]  A. Dorfman,et al.  Inhibition of hyaluronidase. , 1955, Physiological reviews.

[204]  E. Chain,et al.  Identity of Hyaluronidase and Spreading Factor , 1940 .

[205]  G A Harrison,et al.  INSULIN IN ALCOHOLIC SOLUTION BY THE MOUTH , 1923, British medical journal.

[206]  E. Littledike,et al.  Insulin , 1923, Reactions Weekly.

[207]  I. A. Wani,et al.  Recent Advances and Future Prospects , 2019 .

[208]  E. Yuliwati,et al.  A Review , 2019, Current Trends and Future Developments on (Bio-) Membranes.

[209]  Jeremy K Nicholson,et al.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity. , 2017, Translational research : the journal of laboratory and clinical medicine.

[210]  Miguel Montenegro-Nicolini,et al.  Overview and Future Potential of Buccal Mucoadhesive Films as Drug Delivery Systems for Biologics , 2016, AAPS PharmSciTech.

[211]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.

[212]  R. Norton,et al.  Enhancing the Buccal Mucosal Delivery of Peptide and Protein Therapeutics , 2014, Pharmaceutical Research.

[213]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[214]  Josias H. Hamman,et al.  Oral Delivery of Peptide Drugs , 2012, BioDrugs.

[215]  D. Burgess,et al.  Long Acting Injections and Implants , 2012, Advances in Delivery Science and Technology.

[216]  J. Mitri,et al.  Inhaled insulin—what went wrong , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[217]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[218]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.

[219]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[220]  J. Lloreta,et al.  Depot leuprorelin acetate-induced granulomas manifested as persistent suppurative nodules. , 2006, Acta dermato-venereologica.

[221]  H. Benson,et al.  Transdermal drug delivery: penetration enhancement techniques. , 2005, Current drug delivery.

[222]  P. Artursson,et al.  The Influence of Intestinal Mucus Components on the Diffusion of Drugs , 2004, Pharmaceutical Research.

[223]  K. Juni,et al.  Pulmonary Delivery of Salmon Calcitonin Dry Powders Containing Absorption Enhancers in Rats , 2004, Pharmaceutical Research.

[224]  P. Vos,et al.  Cell encapsulation: Promise and progress , 2003, Nature Medicine.

[225]  Johan Smith,et al.  Case reports and review of the literature , 2003 .

[226]  N. Shibata,et al.  Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein. , 2002, Biomaterials.

[227]  I. Wilding,et al.  Enteric coated HPMC capsules designed to achieve intestinal targeting. , 2002, International journal of pharmaceutics.

[228]  B. Silverman,et al.  A Long-Acting Human Growth Hormone (Nutropin Depot®): Efficacy and Safety Following Two Years of Treatment in Children with Growth Hormone Deficiency , 2002, Journal of pediatric endocrinology & metabolism : JPEM.

[229]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[230]  A. Shojaei.  Buccal mucosa as a route for systemic drug delivery: a review. , 1998, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[231]  J. Robinson,et al.  Oral cavity as a site for bioadhesive drug delivery , 1994 .

[232]  Claus-Michael Lehr,et al.  In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers , 1992 .

[233]  H. Halliday.  Surfactant replacement therapy , 1995, Pediatric pulmonology. Supplement.

[234]  S. Muranishi.  Absorption enhancers. , 1990, Critical reviews in therapeutic drug carrier systems.

[235]  J. Verhoef,et al.  Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. , 1990, American journal of respiratory cell and molecular biology.

[236]  F. Theeuwes.  OROS•Osmotic system development , 1983 .